<DOC>
	<DOCNO>NCT00674063</DOCNO>
	<brief_summary>Comparison two dose regimen Alefacept subject weigh 100kg 150kg moderate severe Chronic Plaque Psoriasis</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Two Dosing Regimens Alefacept Subjects Weighing Between 100kg 150kg With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Body weight 100kg 150kg Diagnosis Chronic Plaque Psoriasis Body Surface Area ( BSA ) involvement ≥ 10 % Candidate phototherapy systemic therapy Psoriasis CD4 + T lymphocyte count &gt; low limit normal Clinically significant abnormal hematology value blood chemistry value ALT AST value ≥ 3x upper limit normal Other type Psoriasis Serious infection within 3 month prior 1st dose study drug Antibody positive HIV History malignancy History severe allergic anaphylactic reaction History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal and/or major disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Alefacept</keyword>
</DOC>